NHS Approves Wegovy for Weight Loss and Heart Disease Prevention in Landmark Decision
The National Health Service has reached a significant milestone in its fight against obesity, with experts describing the move as a "major turning point." Wegovy, a weight loss medication, can now be prescribed not only for shedding pounds but also to help reduce the risk of serious cardiovascular events such as heart attacks and strokes.
Green Light from NHS Spending Watchdog
The National Institute for Health and Care Excellence (Nice), the NHS's spending watchdog, has given the green light for semaglutide, marketed as Wegovy, to be administered to overweight and obese patients who also suffer from specific heart and circulatory conditions. This decision aims to cut their risk of major cardiovascular incidents, with a rollout scheduled for the summer.
Expert Acclaim and Cautions
Professor Naveed Sattar, a cardiometabolic medicine expert at the University of Glasgow, praised the development, stating, "We now have medicines that not only reduce heart attacks, strokes, and peripheral arterial disease, but also simultaneously lead to meaningful weight loss." He emphasized that this dual benefit lowers the risk of many weight-related conditions and improves patients' quality of life, calling it a "genuine win-win."
However, experts have issued important cautions. Professor Robert Storey of the University of Sheffield highlighted that GLP-1 receptor agonist drugs like Wegovy can reduce muscle mass as well as fat. He urged prescribers to ensure that the benefits are "balanced against the risk of side effects" and recommended physical activity, such as resistance training, to counteract potential negative effects on muscle strength. This may not be feasible for frail patients, adding a layer of complexity to treatment plans.
Addressing Health Inequalities and Postcode Lotteries
Academics have stressed the need to avoid a postcode lottery in care, urging local health bodies to ensure equitable access when the drugs are introduced. Professor Riyaz Patel from UCL pointed out that other beneficial drugs, like inclisiran for cholesterol lowering, have been variably delivered, leading to significant disparities. He called on integrated care boards to prevent this from happening with Wegovy, warning that failure could exacerbate health inequalities instead of reducing them.
The Role of Physical Activity and Lifestyle Support
Huw Edwards, chief executive of ukactive, welcomed the measure as a "significant step forward" but cautioned that GLP-1 medications are not a standalone solution. He noted that without physical activity, particularly strength training, patients risk losing muscle mass, which can undermine long-term health outcomes. Edwards advocated for combining treatment with structured physical activity and wider lifestyle support to ensure sustainable results.
Broader Implications for Public Health
This guidance represents a shift in how cardiovascular disease is managed, moving beyond a sole focus on lipids and blood pressure to directly address weight. Professor Sattar remarked, "Given that so many people living with cardiovascular disease also struggle with excess weight, it's no longer sufficient to focus solely on lipids and blood pressure. We must also address weight directly if we want to deliver the best possible outcomes for our patients."
Overall, the expansion of Wegovy prescriptions is seen as an exciting development that provides another powerful tool in reducing cardiovascular disease risk, but it requires careful implementation to maximize benefits and minimize risks.
